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Abstract
Acute administration of the psychostimulant amphetamine increases extracellular levels of dopamine
(DA) by reversing the DA transporter on ascending midbrain DA neurons. In vitro studies using
striatal synaptosomal, slice and nucleus accumbens (NAcc) tissue preparations have implicated
protein kinase C (PKC) in this effect. The present study further examined this effect in vivo by
assessing the ability of the PKC inhibitor, Ro31-8220 (10 μM), to inhibit acute amphetamine-induced
DA overflow when applied with this drug to the NAcc via reverse dialysis. Amphetamine was applied
at a concentration of 30 μM and the core and shell subregions of the NAcc were assayed separately
in freely moving rats. These brain regions play a role in the acute locomotor-activating and
motivational effects of amphetamine. Consistent with the findings of previous in vitro experiments,
reverse dialysis of Ro31-8220 with amphetamine robustly attenuated the ability of this drug to
increase extracellular levels of dopamine in both the core and shell subregions of the NAcc. These
results confirm that amphetamine stimulates dopamine overflow via a PKC-dependent mechanism.
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Psychomotor stimulant drugs like amphetamine (AMPH) increase locomotion and support
self-administration [29,30,31]. There is wide-spread acceptance that AMPH produces these
effects through an action-potential independent mechanism by interacting with the dopamine
transporter (DAT) to increase extracellular levels of dopamine (DA) in the nucleus accumbens
(NAcc), the major subcortical projection field of midbrain DA neurons [18,21,26]. The
outward-facing, membrane-bound form of DAT can bind AMPH, transport the drug into the
nerve terminal, release the AMPH in exchange for DA, and transport the neurotransmitter out
of the neuron, releasing it into the extracellular space [5,15,26]. In addition to this exchange
diffusion mechanism, a number of studies have demonstrated that additional intracellular signal
transduction mechanisms may also play a role in AMPH-induced DA release.
There is evidence that the cytoplasmic serine/threonine protein kinase C (PKC) contributes
importantly to AMPH-stimulated DA release. The PKC activator phorbol ester 12-0-
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tetradecanoyl phorbol-13-acetate (TPA) mimics the effect of AMPH by producing an increase
in DA release in striatal slices and synaptosomes, an effect blocked by the DAT antagonists
cocaine and GBR 12935 [3]. Conversely, the PKC inhibitor Ro31-8220 blocks Ca2+-
independent AMPH-induced DA release in rat striatal slices [16]. In addition, perfusion of
NAcc tissue with Ro31-8220 blocks AMPH-stimulated DA release and, when infused into the
NAcc, attenuates locomotor responding to intra-accumbens AMPH [1].
Together, the above findings indicate that PKC activity contributes to AMPH-stimulated DA
release in the striatum and NAcc in vitro. These findings also suggest that inhibiting NAcc
PKC activity in vivo attenuates locomotor responding to NAcc AMPH, presumably by
preventing AMPH-stimulated DA release in this region [18,29]. The present experiments
assessed this possibility by investigating whether reverse dialysis of the selective PKC inhibitor
Ro31-8220 with AMPH attenuates the ability of this drug to increase extracellular levels of
DA in the NAcc in freely moving rats. The core and shell subregions of the NAcc were
investigated as both are known to contribute to the behavioral effects of AMPH [27].
Male Sprague-Dawley rats (Harlan Sprague-Dawley, Madison, WI) weighing 250–275 g upon
arrival were used. They were individually housed in a 12 h light/12 h dark reverse cycle room
with food and water freely available at all times. All experiments were conducted in accordance
with the Declaration of Helsinki and the Guide for the Care and Use of Laboratory animals as
promulgated by the National Institutes of Health. All surgical procedures were conducted
according to an approved Institutional Animal Care and Use Committee protocol.
Starting 3–5 days after arrival, rats were surgically implanted with chronic indwelling cannulae
aimed at the NAcc core or shell. Rats were anesthetized with a ketamine-xylazine mixture (100
mg/kg-6 mg/kg, i.p.), placed in a stereotaxic instrument with the incisor bar 5.0 mm above the
interaural line, and implanted intracranially with bilateral guide cannulae (20 gauge, Plastics
One, Roanoke, VA) aimed at the NAcc core (A/P +3.4 mm, M/L ±1.5 mm, D/V −6.5 to −8.5
mm) or NAcc shell (A/P +3.4 mm, M/L ±0.8 mm, D/V −6.5 to −8.5 mm). D/V coordinates are
expressed from skull surface to the active length of the subsequently inserted microdialysis
probe. Guide cannulae were angled at 10° to the vertical, positioned 5 mm above the ventral-
most aspect of the NAcc [25], and anchored in place with dental cement fixed to stainless steel
screws. Following surgery obturators were inserted into the guide cannulae and rats were
returned to their home cages for a 7–10 day recovery period.
In vivo microdialysis was performed in eight Plexiglass chambers (38 × 32 × 34 cm) with
stainless steel wire floors that were housed inside light- and sound-attenuating ventilated boxes.
On the day before testing, rats were anesthetized briefly with isoflurane and a microdialysis
probe was lowered into the NAcc core or shell. Concentric probes were constructed as
described previously [14] with a 2 mm active surface length and a 5000 MW cutoff. Rats were
placed individually in a testing chamber overnight where they were connected via a steel spring
tether to a liquid swivel and collection vial positioned outside the chamber. Although tethered
during testing, freely moving rats had free access to the entire chamber. Probes were perfused
with aCSF (145 mM Na+, 2.7 mM K+, 1.2 mM Ca2+, 1.0 mM Mg2+, 150 mM Cl−, pH=7.4) at
a flow rate of 0.3 μl/min overnight and 1.5 μl/min during testing. To maximize data collection,
rats were tested on two occasions, once on each side. Because no drugs were administered
systemically during testing, n/group is expressed as probes used (experiments conducted) per
condition.
Samples were collected every 20 minutes for a total of four hours of testing. Three baseline
samples were first collected. One hour into the test session, the PKC inhibitor Ro31-8220 (0,
10 or 100 μM) was added to the aCSF and perfused into the NAcc for the next two hours. Two
hours into the test session, AMPH (0 or 30 μM) was added to the PKC inhibitor and perfused
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into the NAcc for one hour. Three hours into the test session and for the final hour of testing,
the PKC inhibitor and the AMPH were removed from the aCSF. In this way, four treatment
conditions were tested: AMPH alone, AMPH + Ro31-8220, Ro31-8220 alone, and aCSF.
Ro31-8220 methanesulfonate salt and D-AMPH sulfate (Sigma Aldrich, St. Louis, MO) were
dissolved freshly in aCSF either in combination or alone.
Dialysate samples (30 μl) were stored at −80° C until analyzed for DA using HPLC with
electrochemical detection (EC). HPLC-EC was conducted using a single-piston Gilson 302
pump (Gilson, Middleton, WI) set to 1.1 ml/min, a Gilson diaphragm type pulse dampener, a
10 cm ODS-C18 3 mm column (maintained at 35° C), an ESA Model 5100 Coulochem detector
with a conditioning cell (oxidizing at +300 mV) placed prior to a Model 5011 high sensitivity
analytical cell (electrodes set to +50 mV and −350 mV) and a 0.04 M sodium acetate mobile
phase containing 0.3 mM Na2 EDTA, 0.5 mM octyl sodium sulfate and 3.3% acetonitrile (pH
3.75). 25 μl samples were introduced into the mobile phase via a Rheodyne injection valve.
Extracellular concentrations of DA were estimated from peak areas using EZChrom Elite
software. DA eluted at 4.8 min. To control for differences in active surface lengths between
probes, DA concentrations were corrected for individual probe recoveries. These were
determined in vitro at 20° C after each microdialysis testing session and ranged from 5 to 9%.
At the conclusion of the experiment, rats were anesthetized with sodium pentobarbital and
perfused via intracardiac infusion of saline and 10% formalin. Brains were removed and
postfixed in 10% formalin. Coronal sections (40 μm) were mounted onto gelatin-coated slides
and stained with cresyl violet for verification of probe placements. Only subjects with probes
with active surface lengths in the NAcc core or shell were included in the data analyses (Figure
1). Twelve rats were excluded for failing to meet this criterion [AMPH, 2; AMPH + Ro31-8220
(10 μM), 3; Ro31-8220 (10 μM), 1; Ro31-8220 (100 μM), 4; aCSF, 2]. Data were analyzed
with one-way ANOVA followed by post-hoc LSD test comparisons according to Kirk [20].
ANOVA are resistant to violation of the homogeneity of variance assumption. However, the
finding that this assumption was violated and that n/group were unequal required that the data
be subjected to a transformation. The square root transformation was therefore applied to all
the data and the resulting numbers analyzed with one-way ANOVA.
The effects of the different concentrations of Ro31-8220 alone on extracellular DA
concentrations in the NAcc core and shell were first assessed. As shown in Table 1, the highest
concentration of Ro31-8220 (100 μM) by itself significantly increased extracellular
concentrations of DA in both NAcc subregions (p<0.01), indicating that at this concentration
Ro31-8220 produces non-specific effects that precluded further testing. The lower
concentration of Ro31-8220 tested (10 μM) was without significant effects and so was used in
all subsequent experiments.
As illustrated in Figure 2 (NAcc core) and Figure 3 (NAcc shell), 10 μM Ro31-8220
significantly attenuated the ability of AMPH to increase extracellular levels of DA in both
subregions of the NAcc when co-infused with the drug into these sites. No significant group
differences were detected in NAcc DA overflow in either site in the first (aCSF) or second
(Ro31-8220 alone) hours of testing. As expected, extracellular levels of NAcc DA increased
precipitously upon the introduction of AMPH in the third hour of testing, but this increase was
significantly dampened when AMPH was administered with Ro31-8220. One-way ANOVAs
conducted on the maximal DA overflow observed for each animal during this period revealed
a significant effect of groups in both the NAcc core (F3,19=11.56, p<0.001) and NAcc shell
(F3,22=14.68, p<0.001). In the NAcc core, post-hoc LSD tests showed that the AMPH-induced
DA overflow observed in the AMPH+Ro condition was significantly lower than in the AMPH
alone condition (p<0.01, Figure 2 inset) but remained significantly higher than that observed
with Ro31-8220 and aCSF alone (p<0.05). Similar effects were observed in the NAcc shell
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(Figure 3 inset). In this case, the AMPH-induced DA overflow observed with AMPH+Ro was
significantly lower than with AMPH alone (p<0.05) but remained significantly higher than
that observed with Ro31-8220 and aCSF alone (p<0.01). Upon removal of the AMPH and
Ro31-8220 in the fourth hour of testing, extracellular levels of NAcc DA returned rapidly to
those maintained throughout testing by aCSF alone.
The present results show that in vivo reverse dialysis of the PKC inhibitor Ro31-8220 in either
the NAcc core or shell attenuates the ability of AMPH to increase extracellular levels of DA
in these regions. This finding is consistent with previous reports showing that Ro31-8220
inhibits AMPH-stimulated DA release in the NAcc and striatum in vitro [1,16] and extends
others showing that NAcc Ro31-8220 attenuates the locomotor response of AMPH in this site
[1], a behavior associated with this drug’s ability to increase extracellular levels of NAcc DA
[17,18]. Taken together, these findings suggest that PKC influences behavioral responding to
AMPH by regulating DA overflow in the NAcc core and shell.
In contrast to the present findings, a previous study reported that reverse dialysis of the PKC
inhibitor bisindolylmaleimide I (BIM, 30 μM) into the rat striatum did not alter DA release in
response to systemically administered AMPH (5 mg/kg, i.p.) [23]. These findings are difficult
to reconcile. It should be noted however that co-infusion of Ro31-8220 with AMPH into the
NAcc in the present study permitted assessment of the effects of PKC inhibition directly at the
site of AMPH-induced overflow. This was not confounded by the effects AMPH would be
expected to exert, when administered systemically, in sites adjacent to the microdialysis probe
potentially not affected by the PKC inhibition. Additional differences between the two
experiments that may have contributed to the different findings obtained include the different
PKC inhibitors tested and the different brain regions assessed.
Although Ro31-8220 would also be expected to influence PKC activity in non-DA cells in the
NAcc, it is unlikely that these actions could explain its ability to inhibit AMPH-induced NAcc
DA overflow because the latter is Ca2+-independent. Rather, several lines of evidence suggest
that Ro31-8220 produces this effect by altering AMPH-induced reverse transport of DA
through the DAT without affecting AMPH or DA uptake into the DA terminal [1]. There are
known consensus sequences for PKC on the DAT [6] and deleting a region of DAT thought
to include such PKC substrate sites abolishes AMPH-induced DA efflux from DAT expressing
HEK-293 cells [19]. Moreover, the βI and βII isoforms of PKC co-immunoprecipitate with
DAT and overexpressing PKCβII enhances AMPH-stimulated DA efflux again from DAT
expressing HEK-293 cells [13]. In addition, AMPH increases particulate PKC activity [7,8]
and leads to increased PKC phosphorylation of (S41) neuromodulin, the calmodulin-binding
protein thought to modulate transmitter release [10,11]. Although AMPH activates PKC and
results in PKC-dependent phosphorylation, it is not known whether PKC produces its effects
by directly phosphorylating DAT or other DAT-associated proteins [6]. Interestingly, PKC
isoforms also interact with proteins that bind to DAT, such as the receptor for activated C
kinases (RACK1) [22] and the PKCα-binding protein PICK 1 [28]. Taken together, these
results suggest that PKC activity contributes to AMPH-mediated DA overflow by interacting
with the DAT to promote DA efflux. This contribution of PKC was observed in both the NAcc
core and shell even though DAT density is known to be higher in the core relative to the shell
[32] and greater AMPH-induced DA overflow was observed in the former compared to the
latter subregion in the present experiments.
PKC may also enhance AMPH-mediated DA efflux by altering DAT trafficking. AMPH is
known to regulate DAT trafficking. For example, incubation of striatal synaptosomes with
AMPH for short time periods (0.5–1.0 min) increases DAT surface expression [12], while
longer exposure to AMPH leads to DAT internalization [9,33]. Similarly, persistent activation
of PKC increases DAT endocytosis and decreases DAT surface expression [4,33]. Indeed, it
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was recently shown that PKCβ knockout mice show a reduction in DAT surface levels and
altered AMPH-induced DAT trafficking as well as reduced AMPH-stimulated DA efflux
compared to wild-type mice [2]. Thus, it is conceivable that Ro31-8220 inhibited AMPH-
induced DA overflow in the present experiments by preventing the trafficking of DAT to the
membrane. Whatever the case, the present findings clearly demonstrate an important role for
PKC activity in acute AMPH-induced DA overflow in both the NAcc core and shell.
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Figure 1. Location of the active portion of the microdialysis probes in the NAcc core (LEFT) and
shell (RIGHT)
Line drawings are from the atlas of Paxinos and Watson [24]. Numbers to the right indicate
mm from bregma. 36 experiments (18 experiments/side) were conducted in the NAcc core and
38 (19 experiments/side) in the NAcc shell.
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Figure 2. The PKC inhibitor Ro31-8220 attenuates the ability of AMPH to increase extracellular
DA in the NAcc core
Data are shown as group mean (±SEM) extracellular concentrations of DA in the NAcc core
before, during and after reverse dialysis of Ro31-8220 (0 or 10 μM, solid line at abscissa) and
AMPH (0 or 30 μM, dotted line at abscissa). Inset. Results are summarized as group mean
(+SEM) maximal NAcc DA overflow induced by AMPH. Maximal overflow for each animal
was taken as the highest DA peak obtained during reverse dialysis of AMPH. **, p<0.01,
AMPH vs. AMPH + Ro31-8220. Numbers in the legend indicate experiments/group.
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Figure 3. The PKC inhibitor Ro31-8220 attenuates the ability of AMPH to increase extracellular
DA in the NAcc shell
Data are illustrated as described in Figure 2. *, p<0.05, AMPH vs. AMPH + Ro31-8220.
Numbers in the legend indicate experiments/group.
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Table 1
Effects of Ro31-8220 alone on extracellular levels of DA in the NAcc core and shell.
aCSF Ro31-8220 (10 μM) Ro31-8220 (100 μM)
NAcc Core 37.2±8.3 (11) 40.7±9.4 (12) 162.1±53.8 (13) **
NAcc Shell 21.5±4.9 (12) 58.8±7.5 (14) 243.9±85.6 (12) **
Data are shown as group mean (±SEM) maximal DA overflow (pg/25μl) observed after introduction of Ro31-8220 (0, 10 or 100 μM) into the aCSF in
the second hour of testing. Maximal overflow for each animal was taken as the highest DA peak obtained during this period. One-way ANOVA detected
significant effects of groups in the NAcc core (F2,33=6.44, p<0.01) and shell (F2,35=10.53, p<0.001). Post-hoc LSD tests revealed that the 100 μM
concentration significantly increased extracellular DA levels relative to the two other conditions. These did not differ significantly from each other. No
group differences were detected in basal DA levels in the first hour of testing prior to introduction of Ro31-8220.
**
p<0.01, Ro-100 significantly greater than two other groups. Numbers in parentheses indicate experiments/group.
Neurosci Lett. Author manuscript; available in PMC 2010 May 15.
